The AXAL MAA is not as big a deal as some message-board posters would have you believe. For the sake of discussion, let’s say ADXS gets EMA conditional approval to treat second-line metastatic cervical cancer… how much do you think cumulative EU sales will be for a product that was conditionally approved based on single-arm data?
A bigger deal for ADXS (IMHO) is the neoantigen-vaccine (ADXS NEO) collaboration with AMGN. I’ll be (pleasantly) surprised if ADXS’ stock has a big run before the NEO program starts dosing patients.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.